| Contributors: |
Souissi, Amira; Patti, Francesco; Spelman, Tim; Chisari, Clara; Gargouri, Amina; John, Nevin; Kermode, Allan G.; Kalincik, Toma; Butzkueven, Helmut; Sajedi, Seyed Aidin; Lechner-Scott, Jeannette; Roos, Izanne; Laureys, Guy; Taylor, Bruce; Alroughani, Raed; Khoury, Samia J.; Macdonell, Richard; Weinstock-Guttman, Bianca; Havrdova, Eva Kubala; Maimone, Davide; Reddel, Stephen; Fabis-Pedrini, Marzena; Willekens, Barbara; Moghadasi, Abdorreza Naser; Lalive, Patrice; Lugaresi, Alessandra; Ozakbas, Serkan; Solaro, Claudio; Cárdenas-Robledo, Simón; Shaygannejad, Vahid; Etemadifar, Masoud; Boz, Cavit; Eichau, Sara; Tomassini, Valentina; Terzi, Murat; Prat, Alexandre; Habek, Mario; Blanco, Yolanda; Altintas, Ayse; Gerlach, Oliver; Turkoglu, Recai; Buzzard, Katherine; Skibina, Olga; Soysal, Aysun; Van Der Walt, Anneke; Hughes, Stella; Van Pesch, Vincent; Foschi, Matteo; Surcinelli, Andrea; Prevost, Julie; Ramo-Tello, Cristina; Mcguigan, Chri; Sa, Maria Jose; Kuhle, Jen; Spitaleri, Daniele; Singhal, Bhim; Ampapa, Radek; De Gans, Koen; Petersen, Thor; Simu, Mihaela; Lapointe, Emmanuelle; Sanchez-Menoyo, Jose Lui; Gray, Orla; Garber, Justin; Aguera-Morales, Eduardo; Gross-Paju, Katrin; Castillo-Triviño, Tamara; Al-Asmi, Abdullah; Grigoriadis, Nikolao; Inshasi, Jihad; Al-Harbi, Talal; Hardy, Todd A.; Ramanathan, Sudarshini; Cambron, Melissa; Shuey, Neil; Sempere, Angel Perez; Csepany, Tunde; Treviño-Frenk, Irene; Rozsa, Csilla; Cauchi, Marija; Karabudak, Rana; Mrabet, Saloua; Gouider, Riadh |
| Description: |
Multiple Sclerosis (MS) severity is influenced by several factors. Understanding the impact of age at disease onset may help to better characterize clinical and disease features across age groups. This study aimed to characterize the clinical features and disability outcomes of late-onset MS (LOMS) and very late-onset MS (vLOMS), compared to adultonset MS (AOMS). We conducted an observational study using data from the MSBase registry and categorized patients based on age at MS onset: AOMS (18–39 years), transition onset (40–49 years), LOMS (50–59 years), and vLOMS (≥ 60 years). Disease progression was assessed using the 24 week confirmed disability progression, EDSS4 and 6 milestones, conversion to secondary progressive MS(SPMS), and the first progression independent of relapse activity (PIRA) event. Cox proportional hazard regression models were used to determine unadjusted hazard ratios(HR), and propensity score inverse probability of treatment weighting(PS-IPTW) balanced covariate distributions. Among 81,236 patients, 5.2% had LOMS and 1% had vLOMS. Primary progressive MS was more frequent in LOMS and vLOMS (21.7 and 24%, respectively). Patients with LOMS and vLOMS had a significantly increased risk of 24 week confirmed disability progression (HR:LOMS = 1.39, vLOMS = 1.80), EDSS 4 (HR:LOMS = 2.14, vLOMS = 2.95), EDSS 6 (HR:LOMS = 2.33, vLOMS = 6.33), SPMS (HR:LOMS = 1.62, vLOMS = 2.38), and first PIRA event (HR:LOMS = 2.12, vLOMS = 2.93). LOMS and vLOMS exhibited a more progressive disease onset and higher disability milestones compared with AOMS. |